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Abstract
Objectives: To investigate the use of sleep medication and concomitant psychotropic medication in children and adolescents
placed under residential care (RC).
Methods: Participants were youth 0–20 years of age placed in RC institutions at least once during 2016. Data on filled
prescriptions were taken from the Norwegian Prescription Database to compare the use of sleep medication in RC with the
general child population (GenPop) and how it covaried with gender, age, reasons for RC placement, and concomitant use of
other psychotropic medications (antidepressants, anxiolytics, antipsychotics, and psychostimulants).
Results: A total of 2171 youths were identified in RC at mean age 14 years (82% ‡ 13 years). Seventeen percent (371/2171)
used sleep medications (melatonin 11%, alimemazine 7%, and benzodiazepines/z-hypnotics 2%) significantly more than the
2.3% who used in GenPop. The girl/boy ratio for medication use in RC was 1.8 (95% confidence interval [CI] = 1.5–2.2), not
significantly different from the corresponding ratio in GenPop (1.4; 95% CI = 1.3–1.5). The use of sleep medication increased
with age. When comparing reasons for placement in RC, medication use was particularly low among unaccompanied minor
asylum seekers (2%). About half of the youths used concomitant psychotropic medication, with clear gender differences; girls
used about twice as much antidepressants, anxiolytics, and antipsychotics, whereas boys used 1.3 times more psychosti-
mulants.
Conclusion: Youths in RC used more sleep medication and concomitant psychotropic medication than the GenPop, most
likely reflecting the increased psychosocial strain and mental disorders reported in this population. Further studies of
prevalence, assessment, and treatment of sleep problems in RC populations are warranted.
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Introduction
Children and adolescents are placed under residential care(RC) because of severe psychosocial strain, maltreatment,
and/or serious behavioral problems or being unaccompanied minor
asylum seekers. All these placement reasons represent risk factors
for mental disorders (Fazel et al. 2005; Green et al. 2010), and high
rates of psychiatric and/or neurodevelopmental disorders were in-
deed reported in an early study of youths across five sectors of care
(Garland et al. 2001) and later corroborated in a national U.S.
sample (Turney and Wildeman 2016). Similar high rates were
confirmed in a large British study, but in that study, a significantly
higher prevalence was found among children in RC compared with
those in foster care (71% vs. 39%, respectively) (Ford et al. 2007).
The British findings were replicated in Norway, where 76% of youths
in RC were reported to have any psychiatric disorder (Jozefiak et al.
2016) and 52% among those in foster care (Lehmann et al. 2013).
Sleep problems are common in childhood and particularly prev-
alent in children with psychiatric and/or neurodevelopmental disor-
ders (Alfano and Gamble 2009; Baddam et al. 2018; Maski and
Owens 2018). The interaction between sleep and psychopathology
is complex, with significant interrelationships found in the
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development, severity, and prognosis of psychiatric disorders and
their comorbid sleep disturbances (Ramtekkar and Ivanenko 2015).
With regard to age and gender, studies show that although the rates
of sleep problems generally show a slight preponderance among
boys in younger years, girls outnumber boys from puberty onward
( Johnson et al. 2006; Sivertsen et al. 2017).
Studies of sleep problems in children and adolescents in care are
rare, and although studies of psychiatric disorders in youths in care
have been carried out (Lehmann et al. 2013; Jozefiak et al. 2016),
the prevalence of sleep disorders were not reported. However, one
U.S. study found that sleep problems partially mediated the link
between adverse childhood experiences and delinquency among
children in foster care (Hambrick et al. 2018). Furthermore, self-
reported sleep problems were found to be associated with both
anxiety, attention-deficit/hyperactivity disorder (ADHD) symp-
toms, and sexual abuse in Canadian adolescents placed under RC
(Langevin et al. 2019), thus underlining the importance of sleep
problems in vulnerable populations.
Generally, nonpharmacological treatment is the first choice for
sleep problems in children and adolescents, and evidence-based
pharmacological guidelines are not available (Owens and Moturi
2009; Pelayo and Yuen 2012; Economou et al. 2018). This is owing
to the paucity of data available with regard to dosage, efficacy, and
tolerability in youths. Although solid scientific support is missing,
off-label hypnotic medications are frequently used (Stojanovski
et al. 2007), supposedly justified at least by their clinical effec-
tiveness (Bruni et al. 2019). In Norway, melatonin and antihista-
mines were most frequently prescribed in 0- to 17-year-olds (Hartz
et al. 2012), whereas in the United States, where melatonin is
not a prescription medication, antihistamines were most frequently
prescribed (Stojanovski et al. 2007; Meltzer et al. 2014). A recent
review on the pharmacologic treatment for sleep disorders in children
showed that melatonin significantly improved sleep latency, sleep
duration, and wake time after sleep onset, but not number of awak-
enings per night (McDonagh et al. 2019). The medications included in
that review were sedative hypnotics (not benzodiazepines), antihista-
mines, antidepressants (not tricyclic antidepressants), alpha-adrenergic
agonists, antipsychotics, and melatonin. The authors concluded that
melatonin was useful in improving some sleep outcomes in the short
term, particularly when comorbid with neurodevelopmental disorders,
whereas the other sleep medications were considered to be inade-
quately studied.
With regard to the use of psychotropic medications, differential
international variations have been reported in the literature. In a
study comparing 0- to 19-year-olds in three countries, the use of
hypnotics was 33% in the Netherlands, 16% in the United States, and
9% in Germany, whereas United States had the highest use of anti-
depressants and psychostimulants (about three times greater than the
other two), and antipsychotics (about two times greater) (Zito et al.
2008a). For children in foster care, research has shown that they are
far more likely than other children to receive any psychotropic
medication (Kutz 2011; Rubin et al. 2012), and also several different
classes of them (41% received ‡3 different classes) (Zito et al.
2008b). Although psychiatric symptoms are considered the most
salient factors related to use of psychotropic medication in youths,
studies have also shown the influence of demographic characteristics
(Lopez-Leon et al. 2018). No consistent relationship with gender
(Warner et al. 2014), or a male preponderance (Zito et al. 2008b;
Leslie et al. 2010) has been shown, with exceptions from studies
focusing on the specific class of antidepressants, where girls are more
likely to be medicated (Schroder et al. 2017). With regard to age,
estimates of use tend to increase with age, but exceptions are re-
ported; for instance, Zito et al. (2008b) reported highest medication
rates between the ages of 10 and 14 years, compared with both
younger and older youths in foster care.
To the best of our knowledge, studies of the use of sleep medi-
cation within child RC are lacking (for details on our systematic
search in literature databases MEDLINE, EMBASE, and Psy-
cINFO databases, see Supplementary Appendix SA1).
The aim of the study was therefore to investigate the use of sleep
medication in a Norwegian cohort of youths placed in RC, in-
cluding how the use of sleep medication varied with gender, age,
reasons for placement in RC, and the concomitant use of other
psychotropic medication (antidepressants, anxiolytics, antipsy-
chotics, and psychostimulants).
Methods
Study population
Participants were all children and adolescents 0–20 years of age
placed in RC institutions under the Norwegian Directorate for
Children, Youth and Family Affairs, Child Welfare Services
(BUFDIR) at least once during 2016. This directorate is responsible
for all RC institutions in Norway except for those in the munici-
pality of Oslo, which administers its own institutions. Conse-
quently, 80% of Norwegian RC institutions were included in this
study. Available data on the participants were gender, age, and
reasons for placement in RC institutions. Placement reasons in-
clude neglect, emergency placement, serious behavioral problems
of high and low degree, substance abuse, and being unaccompanied
minor asylum seekers.
Prescription drug data
For the RC population, data on all filled prescriptions during
2016 were available from the Norwegian Prescription Database
(NorPD) for each individual. The drugs were classified according to
the Anatomical Therapeutic Chemical (ATC) classification system
version 2018 (World Health Organization [WHO] 2018). We had
information on ATC code and month of dispensing. For the general
population we had information on number of users of the relevant
ATC codes in 2016 in 1-year age groups for boys and girls.
Sleep medication was defined as melatonin (ATC N05CH),
alimemazine/trimeprazine (ATC R06AD01), and benzodiazepines
and the z-hypnotics zopiclone and zolpidem (BZD/Z-HYP’s; ATC
N05CD02, N05CF). Concomitant medication for the following
classes of psychotropic medications were studied: antidepressants
(ATC N06A), anxiolytics (ATC N05B), antipsychotics (ATC
N05A, except N05AN01 [lithium]), and psychostimulants (ATC
N06BA). Concomitant medication was defined as at least one
prescription of sleep medication during 2016 and at least one pre-
scription of the relevant psychotropic medication classes during
2016.
Statistics
We compared the prevalence of prescribed sleep medication and
concomitant psychotropic medication in RC with the age- and
gender-corrected prevalence in the general child population
(GenPop). We also compared boys and girls within and between the
two populations. Mean values, percentages, and prevalence ratios
(PRs) with 95% confidence intervals (CIs) are presented. PR = (n1/
N1)/(n2/N2), where n and N denote number of users and number of
individuals, respectively, in the two populations. Age and gender
correction was carried out using the ageadjust.direct function in the
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R-package epitools, with the study population as reference popu-
lation (1-year age groups). PRs between girls and boys and between
RC and GenPop, with 95% CIs were computed using the risks-
coreci function in the PropCIs package in R (R Development Core
Team 2017). When the numerator and/or the denominator of the PR
was age and gender corrected, the uncertainty involved in the age
and gender correction was taken into account by using a simulation
approach (Supplementary Appendix SA2).
Ethics
The study was approved by The Regional Committee for Med-
ical Research Ethics in South-Eastern Norway (REK), Norwegian
Centre for Research Data and the Norwegian Data Inspectorate
without informed consent under given conditions. These conditions
included data only being handled by one of the authors (V.H.) on a
secure server and destroying the linking key to ensure no possibility
for back identification of individuals. Furthermore, data were
available in 1-year age groups, but are presented in larger intervals
(0–5, 6–12 years, etc.) to ensure anonymity. A personal identifi-
cation number provided by BUFDIR allowed a linkage through the
Norwegian National Register to the NorPD prescription data (ref-
erence: REK 2017/1637).
Results
A total of 2171 youths, 40% girls, were identified in RC at mean
age 14 years (82% ‡ 13 years). Among these, 17% (95% CI= 15.6–
18.7) used sleep medication compared with 2.3% use in GenPop.
Among those who used sleep medication in RC, 64% used mel-
atonin, significantly less than the 74% in GenPop (PR RC/GenPop
[PR]= 0.86; 95% CI=0.77–0.94). Furthermore, 43% used alime-
mazine, significantly more than the 27% in GenPop (PR=1.6; 95%
CI=1.4–1.9), and 12% used BZD/Z-HYP’s, not significantly dif-
ferent from the 9% in GenPop (PR=1.3; 95% CI=0.9–1.8).
In RC, 23% of the girls used sleep medications compared with
13% among boys. The girl/boy ratio for medication use in RC was 1.8
(95% CI=1.5–2.2), not significantly different from the corresponding
ratio in GenPop (PR= 1.4; 95% CI=1.3–1.5). The girl/boy PRs for
the different sleep medications were similar in the two populations
(RC and GenPop, nonsignificant data not shown). See Figure 1 for the
use of different sleep medications showing that boys used more mel-
atonin, whereas girls used more alimemazine (melatonin/alimemazine
ratios were 2.1 [95% CI = 1.7–2.7] and 1.1 [95% CI= 0.9–1.3],
respectively).
The use of sleep medication increased with age in both popu-
lations (RC and GenPop), and in both genders. For girls 13–16
years of age, the use was particularly high compared with GenPop,
see Table 1 for the use of sleep medication for youths in RC, with
ratios RC/GenPop for each age group (0–5, 6–12, 13–16, and 17–20
years).
For those placed in RC owing to being unaccompanied minor
asylum seekers, the use of sleep medication was 2%, and none used
concomitant psychotropic medication. Their use of sleep medica-
tion was equivalent to the use in GenPop (2.2%; 95% CI = 1.1–
4.5%), and significantly lower than for those placed in RC for other
FIG. 1. The use of different sleep medications and their overlaps among girls and boys in residential care.
Table 1. Use of Sleep Medication in Different Age
Groups for Youths in Residential Care
with Prevalence Ratios (RC/GenPop) and 95%
Confidence Intervals
Age, years RC % GenPop %
Ratio RC/GenPop
(95% CI)
All
0–5 1.7 0.6 2.9 (1.1–7.7)
6–12 7.0 1.6 4.4 (2.3–8.0)
13–16 17.1 2.2 7.7 (6.5–9.0)
17–20 23.9 3.2 7.5 (6.4–8.7)
Girls
0–5 2.6 0.5 5.0 (1.6–15.5)
6–12 5.0 1.0 4.9 (1.3–17.1)
13–16 24.7 2.5 10.0 (8.0–12.5)
17–20 31.0 4.2 7.4 (6.1–9.0)
Boys
0–5 0.8 0.6 1.3 (0.2–7.4)
6–12 7.8 1.8 4.3 (2.1–8.3)
13–16 12.8 2.1 6.1 (4.8–7.8)
17–20 17.8 2.4 7.5 (5.8–9.6)
CI, confidence interval; GenPop, general child population; RC,
residential care.
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reasons, mean 19.6% (95% CI = 17.9–21.5). Figure 2 presents the
use of sleep medication related to the different placement reasons.
When comparing all youths who used sleep medication in RC
versus GenPop, the use of concomitant psychotropic medication
was significantly more frequent in RC for all classes, apart from
psychostimulants, where the ratio RC/GenPop was 0.9 (95% CI:
0.7–1.2) (Table 2).
About half of the youths in RC who used sleep medication did
not use other psychotropic medications (45% of the girls, 51% of
the boys). Approximately, another one-third used one concomitant
psychotropic medication (30% of the girls, 35% of the boys). The
use of two concomitant medications was found in 20% of the girls
and 10% of the boys. Finally, three were the maximum number of
concomitant medications used, in 5% of girls, and 4% of boys.
When comparing sleep medicated girls and boys in RC, there
were evident differences in the use of concomitant medication.
Girls used about twice as frequently antidepressants, anxiolytics,
and antipsychotics as boys (girl/boy PRs = 2.3, 95% CI= 1.5–3.5;
2.7, 95% CI = 1.3–5.8; and 1.7, 95% CI = 1.2–2.5, respectively),
and less psychostimulants (girl/boy PR = 0.4, 95% CI = 0.2–0.6).
When investigating girls and boys on sleep medication in the two
populations separately, girls on sleep medication in RC received more
of all classes of psychotropic medications (range of PRs were 1.9–
3.5) apart from psychostimulants (PR=0.6) compared with girls in
GenPop (Table 2). For boys on sleep medication in RC, less treatment
was found for antidepressants and anxiolytics compared with boys in
GenPop (PRs were 0.7 and 0.8), and more treatment with antipsy-
chotics and psychostimulants than boys in GenPop (Table 2).
Discussion
This study compared the use of sleep medication in general,
and their combination with concomitant psychotropic medication,
among youths placed in RC institutions with the age- and gender-
corrected general population (GenPop).
Nearly one in five youths in RC (17%) used sleep medication,
significantly more than the GenPop (2.3%), probably resulting from
the increased psychosocial strain and mental disorders reported in
this population (Ford et al. 2007; Jozefiak et al. 2016). The sleep
medications used were mostly melatonin (64%) and the antihista-
mine alimemazine (43%), consistent with surveys on pharmaco-
logical management of child insomnia (Owens et al. 2010; Heussler
et al. 2013). Fewer youths (12%) used benzodiazepines/z-hypnotics
with potential risk of dependence. It may be positive that the most
commonly prescribed drug was melatonin, for two reasons. (1) The
effect of melatonin is well documented in children, especially for
sleep problems co-occurring with neurodevelopmental disorders
(Bruni et al. 2018; McDonagh et al. 2019). (2) Neurodevelopmental
disorders were found to be highly prevalent in a recent represen-
tative study of youths in Norwegian RC institutions (Autism
spectrum disorders: 24% and ADHD: 33%) ( Jozefiak et al. 2016).
In addition, the fact that boys used more melatonin relative to
alimemazine compared with girls, may support that melatonin was
prescribed particularly to youths with neurodevelopmental disor-
ders, as these disorders are known to be more prevalent in boys
(Suren et al. 2012). For antihistamines, there is lack of randomized
controlled trials, but 1 study of 22 children with night awakenings
found that alimemazine gave moderate improvement of sleep
(France et al. 1999). In addition, the sedating effect has long been
recognized (Yanai et al. 1992), and may explain the frequent use in
this study.
The use of sleep medication increased with age in both popu-
lations, perhaps suggesting that the lack of pharmacological
guidelines restrain clinicians in medicating younger children for
sleep problems. The particular rise in the use of sleep medication in
girls after puberty could result from several factors. A large study
investigating gender differences in children 5–12 years of age
FIG. 2. The use of sleep medication related to the different
placement reasons in residential care (mean percentages with 95%
confidence intervals).
Table 2. Concomitant Psychotropic Medication
in Youths in Residential Care Who Use
Sleep Medication
Drug classes RC % GenPop %
Ratio RC/GenPop
(95% CI)
All
Antidepressants 23 19 1.3 (1.0–1.6)
Anxiolytics 9 6 1.6 (1.1–2.4)
Antipsychotics 25 10 2.6 (2.0–3.2)
Psychostimulants 19 21 0.9 (0.7–1.2)
Girls
Antidepressants 31 17 1.9 (1.4–2.4)
Anxiolytics 13 5 2.5 (1.6–3.9)
Antipsychotics 31 9 3.5 (2.6–4.5)
Psychostimulants 11 18 0.6 (0.4–0.9)
Boys
Antidepressants 14 21 0.7 (0.4–1.0)
Anxiolytics 5 6 0.8 (0.4–1.6)
Antipsychotics 18 11 1.6 (1.1–2.3)
Psychostimulants 30 24 1.3 (0.9–1.6)
Percentages with prevalence ratios RC/GenPop and 95% CIs.
CI, confidence interval; GenPop, general child population; RC residen-
tial care.
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(n = 700) reported that the prevalence of insomnia symptoms in
girls peaked around age 12 (Calhoun et al. 2014). This increase was
associated with objective sleep disturbances, not symptoms of
anxiety and depression, and the authors therefore suggested that the
increase may be related to hormonal changes in girls associated
with the onset of puberty. In addition, the fact that girls in puberty
used particularly more sleep medication relative to the girls in
GenPop, leaves us to speculate whether being in RC could be a
particular strain for girls this age. The significantly lower use of
sleep medication among the unaccompanied minor asylum seekers
in RC (2%) compared with the rest of the youths placed in RC for
other reasons (17%) could point to an overlooked subgroup in RC.
This is in line with a systematic literature review, demonstrating a
general underutilization of mental health services by refugee
children (Colucci et al. 2014), and a recent Norwegian review
(Debesay et al. 2019). This is despite the fact that the prevalence of
mental health problems is known to be higher than in host popu-
lations (Fazel et al. 2005; Fazel 2018).
This study found that the use of concomitant antidepressants
(selective serotonin reuptake inhibitors [SSRIs]), anxiolytics, and
antipsychotics were significantly higher among the sleep-
medicated children and adolescents in RC compared with the sleep
medicated in GenPop. About 23% among the sleep medicated in
RC, also used SSRIs (1.3 times more than in GenPop [95%
CI = 1.1–1.5]), medications usually prescribed to treat depression
and/or anxiety disorders. As SSRIs can promote wakefulness
(Krystal et al. 2013), these may detract from the sleep-promoting
effects of the sleep medications. None of the children and adoles-
cents in RC used tricyclic antidepressants known to promote sleep
(Krystal et al. 2013), and may result from clinicians’ awareness of
the marginal evidence to support the use of tricyclic drugs in the
treatment of depression in adolescents (Hazell and Mirzaie 2013).
Approximately 25% among the sleep medicated in RC used
antipsychotics, about 2.6 times more than in GenPop (ratio
RC/GenPop = 2.6 [95% CI = 2.1–3.0]). This was not unexpected, as
sedating antipsychotics (such as quetiapine, risperidone, and
olanzepine) approved for schizophrenia and bipolar disorder, is
effective at lower doses for insomnia (Asnis et al. 2015). Owing to
side effects, however, antipsychotics are not recommended to im-
prove sleep (Asnis et al. 2015). Although we cannot know with
certainty, the clinicians may also have considered the effect some
antipsychotics may have on calming agitation and/or disruptive
behavior (Loy et al. 2017), as it is unlikely that as many as 1/5 of the
sleep medicated in RC has psychosis or bipolar disorder. The cli-
nicians may also have weighed the additional sleep-promoting ef-
fect as positive. That the antipsychotics used by the participants of
this study may in part have been prescribed to reduce disruptive
behavior is supported by that >20% of the sleep medicated in RC
were registered with ‘‘serious behavioral problems’’ as reasons for
placement.
In this study, about half of the youths in RC who used sleep
medication did not use other psychotropic medications, and the
maximum number of concomitant medications used was three, in
5% of girls, and 4% of boys. This is considerably lower than oc-
currence rates reported in a U.S. study of children in foster care,
where 41% were prescribed three or more psychotropic medica-
tions (Zito et al. 2008b). In line with known epidemiological pat-
terns for antidepressants and psychostimulants in the general youth
population (Sultan et al. 2018), we found that girls in RC used more
medication indicated for anxiety and depression, whereas boys
used more psychostimulants, for which ADHD is the main indi-
cation. However, our findings could suggest an undertreatment with
psychostimulants for girls in RC, in line with a study showing that
girls with ADHD were less likely to receive medication, unless they
also had prominent disruptive symptoms (Mowlem et al. 2019).
Strengths and limitations
A strength of this study is the use of a national prescription
registry, which includes all patients treated with sleep medication
and psychotropic medication in Norway. As such, it provides
valuable information about the filled prescription/dispensed med-
ication in this cohort of youths in RC and may be considered rep-
resentative of clinical practice.
Our study had several limitations. First, although we have valid
data on dispensed medication, and thus, primary nonadherence is
not an issue, we have no knowledge of whether the child actually
took the medication. Second, the NorPD only provides data for
filled prescriptions. Thus, because diagnostic information was not
available, we cannot report on the indications for prescription or the
prevalence of psychiatric disorders. Third, ‘‘concomitant’’ psy-
chotropic medication indicates that they are used during 2016, not
necessarily at the exact same time as sleep medications. However,
this pertains to both populations and the comparison with the
general population is therefore fair. Finally, we do not know
whether the participants were adequately assessed for specific sleep
disorders or offered recommended behavioral interventions for
sleep problems before medication was prescribed.
Conclusions
In this representative population of youths in RC, approximately
one in five used sleep medication, and the percentage of concom-
itant medication could point to a high prevalence of psychiatric
disorders in RC youths medicated for sleep problems. However,
given the high prevalence of psychiatric disorders previously re-
ported in RC populations, the present findings do not necessarily
indicate an overtreatment with medication in RC.
However, the literature has underlined that children with sleep
problems are generally not adequately assessed and treated, and to
which extent this also applies to the vulnerable youths in RC, needs
to be investigated.
Clinical Significance
Clinicians should be aware of that a large proportion of youths in
RC may have sleep problems.
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